Medical consultation scene representing psoriasis treatment options

Psoriasis Treatment Options

Psoriasis Daily Medical Editorial Staff | Last reviewed: March 2026
Medically reviewed by Dr. Rimti, MBBS

Psoriasis treatment has changed greatly in the past 20 years. Options now range from prescription creams to targeted biologic injections. The right approach depends on where your psoriasis shows up, how much skin it covers, and how it affects your daily life. These guides break down your choices so you can have better conversations with your dermatologist.

In This Guide

What Are the Main Types of Psoriasis Treatment?

Psoriasis treatments fall into three broad groups: topicals applied to the skin, light therapy using controlled UV light, and systemic drugs that work throughout the body. Most people start with topical treatments and move to stronger options if those aren’t enough. Biologics, a newer class of systemics, target specific parts of the immune system. They have fewer side effects than older drugs.

Your dermatologist will likely suggest a treatment based on how severe your psoriasis is. Mild disease covering less than 3% of your body may respond well to creams alone. Moderate to severe cases, covering 3% or more, often need light therapy or systemic treatment. About 80% of people with psoriasis have mild to moderate disease, per the National Psoriasis Foundation.

No single treatment works for everyone, and what works for you may change over time. Some drugs lose effect after months or years. That’s why doctors sometimes rotate therapies. The goal is always the same: clearer skin, less pain, and fewer flares.

Learn more: Psoriasis Treatments and Medications: A Complete Guide

Topical Treatments and Phototherapy

Topical treatments include corticosteroids, vitamin D analogs like calcipotriene, and newer options like tapinarof and roflumilast. Phototherapy uses narrowband UVB light two to three times per week to slow skin cell growth. Both approaches work best for mild to moderate psoriasis and can be combined for stronger results.

Topical corticosteroids are still the most widely prescribed psoriasis treatment. They reduce inflammation and slow the overproduction of skin cells that causes plaques. Stronger versions work on thick plaques on elbows and knees. Milder ones are safer for sensitive areas like the face and skin folds.

Light therapy offers a drug-free option. It clears or improves psoriasis in about 75% of people after 15 to 20 sessions. Home UVB units are available by prescription, making this option more practical than it used to be. Your dermatologist can help you weigh ease of use against the time needed for in-office sessions.

Learn more: Topical and Light-Based Psoriasis Treatments

Get Weekly Psoriasis Updates

Treatment breakthroughs, skin care strategies, and community stories.

How Do Biologics Treat Psoriasis?

Biologics treat psoriasis by blocking specific immune proteins that drive skin inflammation. These include TNF-alpha, interleukin-17, and interleukin-23. Given by injection or infusion, biologics can clear 75% to 100% of plaques in many people. Doctors typically prescribe them for moderate to severe psoriasis that hasn’t responded to topicals or older systemic drugs.

Since the first psoriasis biologic was approved in 2003, more than a dozen have reached the market. Newer IL-23 inhibitors like guselkumab (Tremfya) and risankizumab (Skyrizi) need as few as four injections per year. They achieve complete skin clearance in a large share of people treated. IL-17 inhibitors like secukinumab (Cosentyx) and ixekizumab (Taltz) work fast. Many people see results within four weeks.

The main barriers to biologics are cost and access. Without insurance, these drugs can run $30,000 to $70,000 per year. Most makers offer patient assistance programs. Biosimilars are starting to lower prices for older biologics like adalimumab (Humira). Your dermatologist’s office can often help you find coverage options.

Learn more: Biologics for Psoriasis: How They Work, What to Expect

What New Psoriasis Treatments Are in Development?

The psoriasis treatment pipeline includes oral TYK2 inhibitors like deucravacitinib (Sotyktu), approved in 2022. Next-generation IL-17 and IL-23 biologics are also in clinical trials. Researchers are also studying topical JAK inhibitors and combination approaches. These may offer stronger results with fewer side effects.

Deucravacitinib was a turning point as the first oral TYK2 inhibitor for psoriasis. It offers an option for people who prefer pills over injections. Clinical trials showed it outperformed apremilast (Otezla) at 16 weeks. More oral options are in late-stage trials. These could expand choices for people who prefer not to self-inject.

Researchers are also exploring whether earlier, stronger treatment can change the long-term course of psoriasis. Some evidence suggests that starting biologics soon after diagnosis may reduce joint damage in people at risk for psoriatic arthritis. Longer studies are still underway.

Learn more: New and Emerging Psoriasis Treatments

Managing Insurance and Treatment Costs

Psoriasis treatment costs vary widely. With insurance, topical drugs typically cost $10 to $75 per month. Biologics cost much more. List prices can exceed $5,000 per month before insurance. Knowing your options can make good treatment more affordable.

Start by checking if your insurance requires step therapy. This means you must try and fail on cheaper treatments before biologics are covered. Many plans do, and knowing this upfront saves time. If your doctor thinks you need a biologic right away, they can often file a medical exception with supporting records.

Patient assistance programs from biologic makers cover co-pays or provide free drugs for people who qualify. The National Psoriasis Foundation also keeps a list of financial resources. Don’t let cost concerns stop you from asking your dermatologist about treatments that could help.

How Do You Build a Psoriasis Treatment Plan?

Building a psoriasis treatment plan starts with an honest talk with your dermatologist about your symptoms, goals, and preferences. Together you’ll consider how much skin is affected, whether you have joint pain, your comfort with injections, and what you’ve tried. A good plan also includes trigger management, skin care routines, and regular check-ins to adjust treatment.

Before your appointment, take photos of your psoriasis at its worst. Flares don’t always line up with appointments. Showing your doctor what a bad week looks like helps them gauge severity. Write down which treatments you’ve used, how long you tried them, and why you stopped.

Treatment plans aren’t static. Your dermatologist should schedule follow-ups to check how well your current approach works and whether changes are needed. If you’re not seeing meaningful improvement within the expected timeframe for your treatment, say so. You deserve a plan that keeps working for your skin and fits your life.

Learn more: Finding the Right Psoriasis Treatment Plan

Frequently Asked Questions

What is the most effective treatment for psoriasis?
For moderate to severe psoriasis, IL-23 inhibitors like risankizumab (Skyrizi) and guselkumab (Tremfya) consistently show the highest skin clearance rates in clinical trials, with many people achieving complete or near-complete clearance. The most effective treatment for any individual depends on their psoriasis type, severity, and overall health.
How long does it take for psoriasis treatment to work?
Topical corticosteroids can reduce inflammation within days to weeks. Biologics typically show meaningful results within 12 to 16 weeks, with maximum benefit reached by week 24 in most studies. Phototherapy usually takes 15 to 25 sessions, often over 6 to 8 weeks, to produce significant clearing.
Do biologics have serious side effects?
Biologics suppress parts of the immune system, which increases the risk of certain infections. Serious side effects are uncommon but include serious bacterial infections and, with older TNF inhibitors, a small increased risk of certain conditions. Your dermatologist will screen for tuberculosis and hepatitis before starting a biologic and monitor you regularly during treatment.
Is there an oral treatment for psoriasis that isn’t an injection?
Yes. Apremilast (Otezla) and deucravacitinib (Sotyktu) are both oral pills approved for plaque psoriasis. Methotrexate is another older oral option. These are alternatives for people who prefer not to self-inject, though their clearance rates generally fall below those of the newest injectable biologics.
What is step therapy, and does it affect my treatment options?
Step therapy is an insurance requirement that you try and fail on cheaper treatments before coverage kicks in for more expensive ones like biologics. Many insurers require you to try at least two conventional therapies first. Your dermatologist can file a medical exception if they believe you need a biologic right away.
Can I use natural or home remedies alongside my prescribed treatment?
Some complementary approaches, like moisturizing regularly, managing stress, eating anti-inflammatory foods, and using aloe vera or oatmeal baths, can support your treatment plan. Always tell your dermatologist about any supplements or herbal products you’re using, since some interact with prescription medications.
What happens if a biologic stops working for me?
Some people develop antibodies to a biologic over time, which reduces its effectiveness. When this happens, dermatologists typically switch to a biologic from a different class. This process, sometimes called treatment cycling, is common and expected, and your care team will monitor your response at regular intervals.

What Should You Do Next?

If topicals aren’t giving you enough relief, Biologics for Psoriasis: How They Work, What to Expect is the clearest look at modern systemic treatment. For those tracking the latest approvals, New and Emerging Psoriasis Treatments covers the newest options. These include oral TYK2 inhibitors and next-generation biologics. Before your next visit, our guide Psoriasis Treatments and Medications: A Complete Guide gives you the words to ask for what you need.

Others in our community have faced the same insurance battles, side effect questions, and treatment switches. Visit our community forums to hear how they handled it. Or head to Share Your Story to read first-person accounts from people living with psoriasis.

Explore Articles in This Guide

Explore Our Guides

Sources

  1. National Psoriasis Foundation. “Psoriasis Treatment Options.” psoriasis.org. 2024. https://www.psoriasis.org/treatment/
  2. Armstrong AW, et al. “Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.” JAMA Dermatology. 2020. https://doi.org/10.1001/jamadermatol.2019.4029
  3. Menter A, et al. “Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.” Journal of the American Academy of Dermatology. 2019. https://doi.org/10.1016/j.jaad.2018.11.057
  4. Elmets CA, et al. “Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy.” Journal of the American Academy of Dermatology. 2019. https://doi.org/10.1016/j.jaad.2019.04.042
  5. Gordon KB, et al. “Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2).” The Lancet. 2018. https://doi.org/10.1016/S0140-6736(18)31713-6
  6. Reich K, et al. “Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.” Journal of the American Academy of Dermatology. 2022. https://doi.org/10.1016/j.jaad.2021.06.1298
  7. Feldman SR, et al. “Tapinarof cream 1% once daily for the treatment of plaque psoriasis.” New England Journal of Medicine. 2021. https://doi.org/10.1056/NEJMoa2103629
  8. Papp KA, et al. “Guselkumab, an anti-interleukin-23 monoclonal antibody, for moderate-to-severe plaque psoriasis: 2-year efficacy and safety results from VOYAGE 1 and VOYAGE 2.” British Journal of Dermatology. 2018. https://doi.org/10.1111/bjd.16002